Sandoz Is Satisfied With US Pegfilgrastim Start
Promising Initial Signs For Ziextenzo
Executive Summary
Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.